Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
X4 Pharmaceuticalsx4pharma.com · Low evidenceX4 Pharmaceuticals is a biopharmaceutical company focused on developing therapies for rare immune disorders. Their product XOLREMDI (mavorixafor) is the first authorized treatment for patients with WHIM syndrome in the European Union.
Parse Score